Zika Virus Infections - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 175 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H2 2016, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 29 and 21 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Zika Virus Infections Overview 8
Therapeutics Development 9
Pipeline Products for Zika Virus Infections - Overview 9
Pipeline Products for Zika Virus Infections - Comparative Analysis 10
Zika Virus Infections - Therapeutics under Development by Companies 11
Zika Virus Infections - Therapeutics under Investigation by Universities/Institutes 14
Zika Virus Infections - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Zika Virus Infections - Products under Development by Companies 17
Zika Virus Infections - Products under Investigation by Universities/Institutes 20
Zika Virus Infections - Companies Involved in Therapeutics Development 21
Bharat Biotech International Ltd 21
Biken Inc 22
BioCryst Pharmaceuticals Inc 23
Biotron Ltd 24
CaroGen Corp 25
Codagenix Inc 26
Ennaid Therapeutics LLC 27
Etubics Corp 28
GeneOne Life Science, Inc. 29
GeoVax Labs Inc 30
Hawaii Biotech Inc 31
Hemispherx Biopharma Inc 32
HSRx Group 33
Humabs BioMed SA 34
Immunovaccine Inc 35
Kineta Inc 36
Mymetics Corp 37
NewLink Genetics Corp 38
Novavax Inc 39
OXIS International Inc 40
PaxVax Inc 41
Pharos Biologicals LLC 42
Plex Pharmaceuticals Inc 43
Prokarium Ltd 44
Protein Sciences Corp 45
Regeneron Pharmaceuticals Inc 46
Replikins Ltd 47
Sanofi Pasteur SA 48
Sirnaomics Inc 49
Spotlight Innovation Inc 50
Starpharma Holdings Ltd 51
Takeda Pharmaceutical Company Ltd 52
Tamir Biotechnology Inc 53
TGV-Laboratories 54
Themis Bioscience GmbH 55
Valneva SE 56
Vaxart Inc 57
VaxInnate Corp 58
VBI Vaccines Inc 59
Visterra Inc 60
VLP Therapeutics LLC 61
Zika Virus Infections - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Target 63
Assessment by Mechanism of Action 65
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
AGS-v - Drug Profile 71
Alferon LDO - Drug Profile 72
Antibodies to Inhibit Envelope Protein for Dengue Fever and Zika Virus Infection - Drug Profile 74
astodrimer - Drug Profile 75
Drug for Zika Virus Infection - Drug Profile 79
emricasan - Drug Profile 80
galidesivir - Drug Profile 81
GLS-5700 - Drug Profile 84
GOVXZM-01 - Drug Profile 86
HSRx-431 - Drug Profile 87
interferon alfa-n3 - Drug Profile 88
KIN-1400 - Drug Profile 91
Monoclonal Antibody for Zika Virus Infection - Drug Profile 93
Monoclonal Antibody for Zika Virus Infection - Drug Profile 94
mRNA-1325 - Drug Profile 95
MV-4 - Drug Profile 96
niclosamide - Drug Profile 97
P-MAPA - Drug Profile 98
ranpirnase - Drug Profile 100
rintatolimod - Drug Profile 103
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile 111
Small Molecules for Infectious Disease - Drug Profile 112
Small Molecules for Zika Virus Infection - Drug Profile 113
Small Molecules for Zika Virus Infection - Drug Profile 114
Small Molecules for Zika Virus Infections - Drug Profile 115
Small Molecules for Zika Virus Infections - Drug Profile 116
Small Molecules to Inhibit Nonstructural Protein for Zika Virus Infection - Drug Profile 117
STP-602 - Drug Profile 118
Synthetic Peptide for Zika Virus Infection - Drug Profile 119
Synthetic Peptides to Inhibit Matrix Protein for Zika Virus Infections - Drug Profile 120
TAK-426 - Drug Profile 121
VIS-ZKV - Drug Profile 122
VLA-1601 - Drug Profile 123
VRC-5283 - Drug Profile 124
VRC-5288 - Drug Profile 125
Zika [strain ZIKV/Hu/Chiba/S36/2016] virus vaccine - Drug Profile 127
Zika virus (bivalent, virus like particle) vaccine - Drug Profile 128
Zika virus (virus like particle) vaccine - Drug Profile 129
Zika virus (virus like particle) vaccine - Drug Profile 130
Zika virus vaccine - Drug Profile 131
Zika virus vaccine - Drug Profile 132
Zika virus vaccine - Drug Profile 133
Zika virus vaccine - Drug Profile 134
Zika virus vaccine - Drug Profile 136
Zika virus vaccine - Drug Profile 137
Zika virus vaccine - Drug Profile 138
Zika virus vaccine - Drug Profile 139
Zika virus vaccine - Drug Profile 140
Zika virus vaccine - Drug Profile 141
Zika virus vaccine - Drug Profile 142
Zika virus vaccine - Drug Profile 143
Zika virus vaccine - Drug Profile 144
Zika virus vaccine - Drug Profile 145
Zika virus vaccine - Drug Profile 146
Zika virus vaccine - Drug Profile 147
Zika virus vaccine - Drug Profile 148
Zika virus vaccine - Drug Profile 149
Zika virus vaccine - Drug Profile 150
Zika virus vaccine 1 - Drug Profile 151
Zika virus vaccine 1 - Drug Profile 152
Zika virus vaccine 1 - Drug Profile 153
Zika virus vaccine 1 - Drug Profile 154
ZIKV-117 - Drug Profile 155
ZIKV-rEfl - Drug Profile 156
Zika Virus Infections - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 169
Disclaimer 170

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2016 14
Number of Products under Development for Zika Virus Infections - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2016 25
Zika Virus Infections - Pipeline by Bharat Biotech International Ltd, H2 2016 26
Zika Virus Infections - Pipeline by Biken Inc, H2 2016 27
Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2016 28
Zika Virus Infections - Pipeline by Biotron Ltd, H2 2016 29
Zika Virus Infections - Pipeline by CaroGen Corp, H2 2016 30
Zika Virus Infections - Pipeline by Codagenix Inc, H2 2016 31
Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, H2 2016 32
Zika Virus Infections - Pipeline by Etubics Corp, H2 2016 33
Zika Virus Infections - Pipeline by GeneOne Life Science, Inc., H2 2016 34
Zika Virus Infections - Pipeline by GeoVax Labs Inc, H2 2016 35
Zika Virus Infections - Pipeline by Hawaii Biotech Inc, H2 2016 36
Zika Virus Infections - Pipeline by Hemispherx Biopharma Inc, H2 2016 37
Zika Virus Infections - Pipeline by HSRx Group, H2 2016 38
Zika Virus Infections - Pipeline by Humabs BioMed SA, H2 2016 39
Zika Virus Infections - Pipeline by Immunovaccine Inc, H2 2016 40
Zika Virus Infections - Pipeline by Kineta Inc, H2 2016 41
Zika Virus Infections - Pipeline by Mymetics Corp, H2 2016 42
Zika Virus Infections - Pipeline by NewLink Genetics Corp, H2 2016 43
Zika Virus Infections - Pipeline by Novavax Inc, H2 2016 44
Zika Virus Infections - Pipeline by OXIS International Inc, H2 2016 45
Zika Virus Infections - Pipeline by PaxVax Inc, H2 2016 46
Zika Virus Infections - Pipeline by Pharos Biologicals LLC, H2 2016 47
Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2016 48
Zika Virus Infections - Pipeline by Prokarium Ltd, H2 2016 49
Zika Virus Infections - Pipeline by Protein Sciences Corp, H2 2016 50
Zika Virus Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 51
Zika Virus Infections - Pipeline by Replikins Ltd, H2 2016 52
Zika Virus Infections - Pipeline by Sanofi Pasteur SA, H2 2016 53
Zika Virus Infections - Pipeline by Sirnaomics Inc, H2 2016 54
Zika Virus Infections - Pipeline by Spotlight Innovation Inc, H2 2016 55
Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, H2 2016 56
Zika Virus Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 57
Zika Virus Infections - Pipeline by Tamir Biotechnology Inc, H2 2016 58
Zika Virus Infections - Pipeline by TGV-Laboratories, H2 2016 59
Zika Virus Infections - Pipeline by Themis Bioscience GmbH, H2 2016 60
Zika Virus Infections - Pipeline by Valneva SE, H2 2016 61
Zika Virus Infections - Pipeline by Vaxart Inc, H2 2016 62
Zika Virus Infections - Pipeline by VaxInnate Corp, H2 2016 63
Zika Virus Infections - Pipeline by VBI Vaccines Inc, H2 2016 64
Zika Virus Infections - Pipeline by Visterra Inc, H2 2016 65
Zika Virus Infections - Pipeline by VLP Therapeutics LLC, H2 2016 66
Assessment by Monotherapy Products, H2 2016 67
Number of Products by Stage and Target, H2 2016 69
Number of Products by Stage and Mechanism of Action, H2 2016 71
Number of Products by Stage and Route of Administration, H2 2016 73
Number of Products by Stage and Molecule Type, H2 2016 75